arrow
K

Krzysztof Brzózka

ryvu therapeutics sa
H指数:19
被引数:4,651

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrated transcriptomic and functional modeling reveals AKT and mTOR synergy in colorectal cancer

整合转录组学和功能建模揭示AKT和mTOR在结直肠癌中的协同作用

2025-07-310
OA
MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma (vol 127, pg 4179, 2017)
2024-04-151
OAAI
Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers
2024-03-220
PRE
Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors
2024-03-220
PRE
Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies
2021-12-0123
OA
NOVEL, ORALLY ADMINISTERED HPK1 INHIBITORS DEMONSTRATE ANTI-TUMOR EFFICACY AND ENHANCED IMMUNE RESPONSE
2021-11-101
OA
CHARACTERIZATION OF RVU-27065 A NOVEL SMALL-MOLECULE STING AGONIST SUITABLE FOR SYSTEMIC ADMINISTRATION
2021-11-100
OA
Discovery of indazole-pyridinone derivatives as a novel class of potent and selective MNK1/2 kinase inhibitors that protecting against endotoxin-induced septic shock
2021-03-016
PREAI
In vivo and in vitro characterization of RVU330 best-inclass dual A2A/A2B adenosine receptor antagonist
2020-08-150
PRE
Development of selective small molecule STING agonists suitable for systemic administration
2020-08-153
PRE